Recursion, which has partnered with drugmakers such as Bayer and Roche, plans to use Nvidia’s software to support its own pipeline as well as current and future partners.
https://www.pharmalive.com/wp-content/uploads/2023/07/Nvidia.jpg600688Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2023-07-12 08:54:042023-07-12 10:15:57Nvidia invests $50 million in Recursion to train AI models for drug discovery
